Research News
View articles by month and year
-
Radiation and Hormonal Therapy After DCIS Surgery Lowers Recurrence Risk
After DCIS surgery, radiation therapy seems to be better at lowering the risk of cancer in the same breast while hormonal therapy seems to be better at lowering the risk of cancer in the opposite breast.
-
Higher Faslodex Dose More Effective Against Metastatic Breast Cancer
Advanced-stage, hormone-receptor-positive breast cancers treated with 500 mg of Faslodex (double the usual dose) had a slightly better response than cancers treated with 250 mg of Faslodex (the usual dose).
-
Hormonal Therapy for Breast Cancer Seems to Reduce Lung Cancer Risk
A large Swiss study suggests that estrogen plays a role in the development, growth, and spread of lung cancer.
-
Research Continues to Show Benefit of Chemotherapy After Breast Cancer Surgery
Research suggests that post-menopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer that had spread to the lymph nodes who got adjuvant chemotherapy AND adjuvant hormonal therapy had a lower risk of recurrence and were more likely to be alive than women who got only hormonal therapy. The study also showed that starting hormonal therapy after chemotherapy was done was better than giving hormonal therapy and chemotherapy at the same time and that a genetic test can help figure out if women diagnosed with early-stage, hormone-receptor-positive breast cancer that has spread to the lymph nodes will benefit from adjuvant chemotherapy.
-
Same Outcomes for Women Who Take Aromasin for 5 Years or Switch After Taking Tamoxifen
The latest results from the TEAM trial show that women who took tamoxifen for 2.5 to 3 years and then switched to Aromasin for 2 to 2.5 years (for a total of 5 years of hormonal therapy) had the same risk of recurrence as women who took Aromasin for 5 years.
-
Breast Cancers with Activated Estrogen Receptor More Sensitive to Tamoxifen
Research suggests that hormone-receptor-positive breast cancers with an activated form of estrogen receptor (ER alpha S118-P) benefited from tamoxifen treatment; cancers without the activated form didn't benefit from tamoxifen.
-
Low Levels of CYP2D6 Enzyme Affect Tamoxifen’s Effectiveness
Tamoxifen isn't as effective in women diagnosed with early-stage, hormone-receptor-positive breast cancer who make very little or no CYP2D6 enzyme compared to women with higher CYP2D6 levels.
-
Research Suggests Link Between Tamoxifen and Risk of Hormone-Receptor-Negative Cancer in Opposite Breast
Research suggests that there may be a link between taking taking tamoxifen for 5 years and a higher risk of developing hormone-receptor-negative cancer in the opposite breast.
-
Compared to Tamoxifen, 5 Years of Femara Improves Survival
Taking Femara (chemical name: letrozole) for 5 years as the first adjuvant hormonal therapy medicine improved overall survival by 13% compared to taking tamoxifen for 5 years.
-
Estradiol Therapy May Help Some Advanced-Stage Breast Cancers Start Responding to Hormonal Therapy Again
A small study found that estradiol, a form of estrogen, was an effective treatment for about 30% of advanced-stage, hormone-receptor-positive breast cancers that had stopped responding to hormonal therapy.
